Amivantamab + lazertinib showed survival benefit over osimertinib in 1L NSCLC with classical EGFR mutations
https://www.targetedonc.com/view/amivantamab-and-lazertinib-combo-extends-survival-in-egfr-nsclc
Meanwhile sunvozertinib, an amivantamab contender in exon20 EGFR-mutated NSCLC, was granted priority review by the FDA
https://www.onclive.com/view/sunvozertinib-under-fda-priority-review-for-nsclc-with-egfr-exon-20-insertion-mutations
https://www.targetedonc.com/view/amivantamab-and-lazertinib-combo-extends-survival-in-egfr-nsclc
Meanwhile sunvozertinib, an amivantamab contender in exon20 EGFR-mutated NSCLC, was granted priority review by the FDA
https://www.onclive.com/view/sunvozertinib-under-fda-priority-review-for-nsclc-with-egfr-exon-20-insertion-mutations
Comments